EMA panel recommends nirogacestat for desmoid tumors

Published 20/06/2025, 13:06
EMA panel recommends nirogacestat for desmoid tumors

STAMFORD, Conn. - The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended approval of nirogacestat for treating adults with progressing desmoid tumors requiring systemic treatment, SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a $3.5 billion market cap biotech company with impressive 93% gross profit margins, announced Friday. According to InvestingPro data, the company maintains strong financial health with more cash than debt on its balance sheet.

If approved by the European Commission, which is expected to make its final decision in the third quarter of 2025, nirogacestat would become the first authorized therapy for desmoid tumors in the European Union.

The CHMP recommendation is based on results from the Phase 3 DeFi trial published in The New England Journal of Medicine. The study showed nirogacestat reduced the risk of disease progression by 71% compared to placebo and demonstrated significant improvement in objective response rate and patient-reported outcomes including pain, physical functioning and quality of life. This development has contributed to SpringWorks’ remarkable revenue growth of over 730% in the last twelve months, as reported by InvestingPro.

Desmoid tumors are rare, aggressive soft tissue tumors that can be debilitating and sometimes life-threatening. An estimated 1,300-2,300 new cases are diagnosed annually in the European Union, with higher prevalence in females.

"The positive CHMP opinion reflects the meaningful benefits nirogacestat can offer patients in Europe where currently there are no approved treatment options," said Saqib Islam, Chief Executive Officer of SpringWorks, in a press release statement.

The most common adverse reactions reported in patients receiving nirogacestat included diarrhea, ovarian toxicity, rash, nausea, fatigue, and stomatitis.

Nirogacestat previously received Orphan Drug designation from the European Commission for soft tissue sarcoma treatment and is already approved in the United States for adults with progressing desmoid tumors requiring systemic treatment. The stock has shown strong momentum with a 31% gain over the past six months. For deeper insights into SpringWorks’ financial health, growth prospects, and 6 additional exclusive ProTips, visit InvestingPro, where you’ll find comprehensive analysis in our detailed Pro Research Report.

In other recent news, SpringWorks Therapeutics has made notable strides in its merger with Merck KGaA, having received necessary regulatory clearances from German and U.S. antitrust authorities. The merger, expected to finalize in the second half of 2025, awaits shareholder approval, with a special meeting arranged to vote on the agreement. SpringWorks is also approaching a significant milestone in Europe, as the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended conditional marketing authorization for mirdametinib, a treatment for neurofibromatosis type 1. Meanwhile, H.C. Wainwright has maintained a Buy rating on SpringWorks, with a price target of $74, reflecting optimism about the potential approval of nirogacestat for desmoid tumors in Europe.

In contrast, TD Cowen has downgraded SpringWorks from Buy to Hold, adjusting the price target to $47, citing the proposed acquisition by Merck KGaA. The firm views the acquisition as strategically beneficial, enhancing Merck’s oncology portfolio without overlapping pipelines. SpringWorks recently held its annual stockholders’ meeting, where key resolutions, including the election of directors and the ratification of its accounting firm, were passed. Investors are closely monitoring these developments, as they present significant implications for SpringWorks’ strategic direction and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.